L Piroth

Summary

Affiliation: CHU de Dijon
Country: France

Publications

  1. ncbi request reprint Acute liver enzyme elevations in HIV-1-infected patients
    Claire Livry
    Centre Régional de Pharmacovigilance de Bourgogne, Hopital General, CHU Dijon, France
    HIV Clin Trials 4:400-10. 2003
  2. doi request reprint [HIV-HCV co-infection: where are we now?]
    L Piroth
    Département d infectiologie, CHU, Dijon, France
    Gastroenterol Clin Biol 33:S94-6. 2009
  3. pmc Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study
    Lionel Piroth
    Département d infectiologie, CHU Dijon, Dijon, France
    BMC Infect Dis 14:287. 2014
  4. pmc Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients
    Thiphaine Ansemant
    Infectious Diseases Department, CHU, Dijon, 21079, France
    BMC Infect Dis 13:7. 2013
  5. ncbi request reprint Liver steatosis in HIV-infected patients
    Lionel Piroth
    Service des Maladies Infectieuses et Tropicales CHU, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon, France
    AIDS Rev 7:197-209. 2005
  6. doi request reprint A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients
    L Piroth
    Department of Infectious Diseases, CHU Dijon, and Université de Bourgogne, Dijon, F 21000, France
    Epidemiol Infect 139:1835-44. 2011
  7. ncbi request reprint Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study
    Lionel Piroth
    Infectious Diseases Department, University Hospital, and University of Burgungy, Dijon, France
    Hepatology 52:1915-21. 2010
  8. doi request reprint Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon and Université de Bourgogne, France
    J Hepatol 53:1006-12. 2010
  9. ncbi request reprint Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
  10. doi request reprint Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy
    Lionel Piroth
    Service des Maladies Infectieuses, CHU Dijon, 10, Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    J Hepatol 49:892-8. 2008

Detail Information

Publications62

  1. ncbi request reprint Acute liver enzyme elevations in HIV-1-infected patients
    Claire Livry
    Centre Régional de Pharmacovigilance de Bourgogne, Hopital General, CHU Dijon, France
    HIV Clin Trials 4:400-10. 2003
    ..By comparison, the frequency and the risk factors of ALEE in untreated patients and in patients treated with several antiretroviral regimens need to be assessed...
  2. doi request reprint [HIV-HCV co-infection: where are we now?]
    L Piroth
    Département d infectiologie, CHU, Dijon, France
    Gastroenterol Clin Biol 33:S94-6. 2009
    ....
  3. pmc Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study
    Lionel Piroth
    Département d infectiologie, CHU Dijon, Dijon, France
    BMC Infect Dis 14:287. 2014
    ..Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed...
  4. pmc Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients
    Thiphaine Ansemant
    Infectious Diseases Department, CHU, Dijon, 21079, France
    BMC Infect Dis 13:7. 2013
    ....
  5. ncbi request reprint Liver steatosis in HIV-infected patients
    Lionel Piroth
    Service des Maladies Infectieuses et Tropicales CHU, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon, France
    AIDS Rev 7:197-209. 2005
    ..Nevertheless, while waiting for prospective studies in HIV-infected patients, improved recognition, diagnosis and management of steatosis are required in these patients...
  6. doi request reprint A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients
    L Piroth
    Department of Infectious Diseases, CHU Dijon, and Université de Bourgogne, Dijon, F 21000, France
    Epidemiol Infect 139:1835-44. 2011
    ..Immediate HAART is beneficial in patients with a baseline HIV viral load 5 log10 copies/ml, whereas deferred HAART appears to be the best option for patients with CD4 ≥350/mm3 and baseline HIV viral load <3·5 log10 copies/ml...
  7. ncbi request reprint Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study
    Lionel Piroth
    Infectious Diseases Department, University Hospital, and University of Burgungy, Dijon, France
    Hepatology 52:1915-21. 2010
    ..4%) and with effective duration of HCV therapy (64.3% for 24 ± 4 weeks versus 92.0% for longer treatment; P = 0.03)...
  8. doi request reprint Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon and Université de Bourgogne, France
    J Hepatol 53:1006-12. 2010
    ..To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients...
  9. ncbi request reprint Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
    ..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...
  10. doi request reprint Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy
    Lionel Piroth
    Service des Maladies Infectieuses, CHU Dijon, 10, Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    J Hepatol 49:892-8. 2008
    ..We aimed to assess the prevalence of GBV-C, SEN-V and occult HBV infections, their impact on HCV and HIV infections and on the response to HCV therapy in HIV-HCV co-infected patients...
  11. ncbi request reprint Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)?
    Lionel Piroth
    Service des Maladies, Infectieuses et Tropicales, Hôpital d Enfants, CHU Dijon, France
    Eur J Epidemiol 19:597-604. 2004
    ..However, the CD4 decay slope after 3 years, the risk of therapeutic side-effects and the low risk of clinical progression do not support systematic treatment of those patients...
  12. doi request reprint Treatment of chronic hepatitis C in HIV-infected patients: from clinical trials to field practice
    Lionel Piroth
    Infectious Diseases Department, Centre Hospitalier Universitaire, Dijon, France
    Scand J Infect Dis 40:561-4. 2008
    ..These results argue for earlier, more frequent and improved HCV treatment in HIV-infected patients...
  13. ncbi request reprint Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy
    M Duong
    Division of Infectious Diseases, Department of Endocrinology, and Division of Hepatology, University Hospital, Dijon, France
    J Acquir Immune Defic Syndr 27:245-50. 2001
    ..Our findings suggest that chronic HCV infection is a significant factor associated with the development of metabolic abnormalities and with modifications in body composition in HIV patients receiving antiretroviral treatment...
  14. ncbi request reprint Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response
    M Duong
    Division of Infectious Diseases, University Hospital, Dijon, 21034, France
    Clin Infect Dis 33:386-92. 2001
    ..006). PI level was the higher significant predictor of virologic response (P=.0003). Self-reported adherence (P=.01) and macrocytosis (P=.05) were also independently associated with antiretroviral efficacy...
  15. ncbi request reprint Incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy
    L Piroth
    Department of Infectious Diseases, University Hospital of Dijon, France
    Scand J Infect Dis 33:559-60. 2001
    ..8/100 patient-years, with a prevalence of 2.8% in those treated for > or = 2 y. Even though the physiopathology remains unclear, this study suggests that gynecomastia should be monitored in these patients...
  16. ncbi request reprint Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens
    M Duong
    Division of Infectious Diseases, University Hospital, Dijon, France
    HIV Clin Trials 2:128-35. 2001
    ..To improve the feasibility and the reproducibility of the PMAQ, we propose a revised form of the PMAQ, focusing on the variables identified as strong predictors of adherence...
  17. ncbi request reprint Limitation of exercise capacity in nucleoside-treated HIV-infected patients with hyperlactataemia
    M Duong
    Service des Maladies Infectieuses, Hopital Universitaire du Bocage, Dijon, France
    HIV Med 8:105-11. 2007
    ..Hyperlactataemia, which is a consequence of a shift in the metabolism of pyruvate, is an indicator of nucleoside-related mitochondrial toxicity...
  18. doi request reprint Markov modelling of HIV infection evolution in the HAART era
    C Binquet
    Department of Medical Informatics and Biostatistics, CHRU Dijon, Dijon, F 21000, France
    Epidemiol Infect 137:1272-82. 2009
    ..This model provides 'real life' transition probabilities from one immunological stage to another, allowing decision analyses that could help determine the beneficial therapeutic strategies for HIV-infected patients...
  19. ncbi request reprint Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review
    M Duong
    Service des Maladies Infectieuses, Centre Hospitalo-Universitaire de Dijon, Hopital du Bocage, France
    Clin Cardiol 24:690-4. 2001
    ..Evaluation and control of risk factors for CHD should be performed in each patient for whom treatment with a PI is indicated...
  20. ncbi request reprint HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study
    J M Petit
    Service d'Endocrinologie, , Dijon, France
    Horm Metab Res 32:367-72. 2000
    ..These results suggest that PI could be responsible for the development of hypertriglyceridemia by a mechanism independent of insulin resistance which remains to be elucidated...
  21. ncbi request reprint Therapeutic trials in HIV infection: which benefits for which patients?
    L Piroth
    Service des Maladies Infectieuses et Tropicales, Hôpital d Enfants, CHU Dijon, France
    HIV Clin Trials 2:22-30. 2001
    ....
  22. ncbi request reprint [Pyogenic psoas abscess: six cases and review of the literature]
    S Audia
    Service des Maladies Infectieuses et Tropicales, Hôpital d Enfants, CHU de Dijon, 10, Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    Rev Med Interne 27:828-35. 2006
    ..Psoas abscess is a rare disease in developed countries. Its diagnosis is difficult and any delay could lead to a worsen prognosis. The aim of this study is to determine the best diagnostic and therapeutic practices...
  23. doi request reprint [Factors influencing the prescription or non-prescription of antibiotics by general practitioners]
    H Faure
    Département d infectiologie, CHU de Dijon, 21079 Dijon Cedex, France
    Med Mal Infect 39:714-21. 2009
    ....
  24. ncbi request reprint Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
    Jean Michel Petit
    CHU Dijon, France
    Antivir Ther 15:797-800. 2010
    ....
  25. doi request reprint [Incidence, prevalence and risk factors for a first infectious complication on a totally implantable venous-access port]
    M Crisinel
    Département d infectiologie, CHU de Dijon, France
    Med Mal Infect 39:252-8. 2009
    ..Totally implantable venous-access ports (TIVAP) should present less risk of complications than central venous catheters over a long time period...
  26. ncbi request reprint [Is there an increased risk for cardiovascular disease in HIV-infected patients on antiretroviral therapy?]
    M Duong
    Service des Maladies Infectieuses, centre hospitalier régional universitaire CHRU du Bocage, 21034 Dijon, France
    Ann Cardiol Angeiol (Paris) 52:302-7. 2003
    ..Despite these uncertainties, it seems reasonable to identify and manage cardiovascular risk factors in HIV infected patients...
  27. ncbi request reprint Informal consultation at a teaching hospital infectious diseases department
    C Rameau
    Infectious Diseases Department, Dijon Teaching Hospital, BP 97908, 21000 Dijon, France
    Med Mal Infect 44:107-11. 2014
    ..Informal consultations for advice in the infectious diseases department (IDD) induce a significant workload for physicians. Our aim was to retrospectively quantify and describe this activity in our institution...
  28. doi request reprint [Measure of effectiveness and adherence to antiretroviral therapy in HIV-infected patients in Cameroon]
    S Mahy
    Département d infectiologie, Hôpital d Enfants, CHU de Dijon, Boulevard Marechal De Lattre de Tassigny, Dijon, France
    Med Mal Infect 41:176-80. 2011
    ..The aim of the study was to identify the most useful clinical criteria to measure effectiveness and adherence to antiretroviral treatment in a rural area of Cameroon...
  29. ncbi request reprint [Recurrent atypical mycobacterial infections in the adult: think of autoantibodies against interferon-gamma !]
    J B Picque
    Département d infectiologie, CHU de Dijon, 2, Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    Rev Med Interne 33:103-6. 2012
    ..They have been mainly reported in AIDS patients. Cases related to the presence of anti-interferon-γ autoantibodies are rare...
  30. doi request reprint Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients
    B Martha
    Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Dijon, France
    Clin Microbiol Infect 16:617-23. 2010
    ..Mucoid transition of Pa was associated with variables that reflected the severity of both lung disease and Pa colonization. Although they do not lead to prophylactic measures, these results corroborate the need to avoid Pa persistence...
  31. doi request reprint [Vaccination coverage of healthcare professionals in an infectious diseases department]
    M Duong
    Département d infectiologie, Hopital du Bocage, CHU, Boulevard Marechal De Lattre de Tassigny, 21000 Dijon, France
    Med Mal Infect 41:135-9. 2011
    ..The study's objective was to evaluate with a standardized questionnaire the knowledge of healthcare workers (HCWs) regarding occupational vaccinations and their vaccination coverage...
  32. doi request reprint Occult hepatitis B in HIV-HCV coinfected patients
    Lionel Piroth
    Service des Maladies Infectieuses et Tropicales, CHU Dijon, France
    Scand J Infect Dis 40:835-9. 2008
    ....
  33. doi request reprint Emergence of tularemia in France: paradigm of the Burgundy region
    S Mahy
    Centre Hospitalier Universitaire de Dijon, Universite de Bourgogne, Dijon, France
    Int J Infect Dis 15:e882-3. 2011
    ..These cases highlight the increased incidence and geographical spread of tularemia in France, and the usefulness of real-time PCR technology for the early diagnostic confirmation of tularemia...
  34. doi request reprint Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital
    P Cassier
    Service d hygiène et d épidémiologie hospitalière, University Hospital, Dijon, France
    Clin Microbiol Infect 17:1746-51. 2011
    ..50). This report highlights the dramatic increase of CTX-M-producing E. coli and the need for changes in the use of antimicrobial drugs and in infection control measures to manage this major health concern...
  35. pmc Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae
    N Desbiolles
    Infectious Diseases Department and EA562, University Hospital, Dijon, France
    Antimicrob Agents Chemother 45:3328-33. 2001
    ..Consequently, either of the combinations can be proposed for use for the treatment of PRP infections...
  36. doi request reprint Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
    M A Valantin
    Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 65:556-61. 2010
    ..To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters...
  37. ncbi request reprint Arthritis following combined vaccine against diphtheria, polyomyelitis, and tetanus toxoid
    J F Maillefert
    Department of Rheumatology, Dijon University Hospital, France
    Clin Exp Rheumatol 18:255-6. 2000
    ..Although our cases suggest that immunization against diphtheria, poliomyelitis and tetanus toxoid may cause arthritis, additional cases must be reported before studies aimed at confirming this possibility are considered...
  38. ncbi request reprint Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice
    Michel Duong
    Division of Infectious Diseases, University Hospital, Dijon, France
    HIV Clin Trials 5:216-23. 2004
    ..Clinical trials have shown that therapeutic drug monitoring (TDM) of antiretrovirals (ARV) improves patient care. However, little is known about the usefulness of TDM in routine practice...
  39. ncbi request reprint Influence of positive end-expiratory pressure (PEEP) on histopathological and bacteriological aspects of pneumonia during low tidal volume mechanical ventilation
    Pierre Emmanuel Charles
    Laboratoire des Maladies Infectieuses, EA562, Dijon University Hospital, boulevard Mal de Lattre de Tassigny, 21033 Dijon, France
    Intensive Care Med 30:2263-70. 2004
    ..The influence of the PEEP level was investigated on bacteriology and histology in a model of ventilator-associated pneumonia...
  40. ncbi request reprint Performance of a predictive rule to distinguish bacterial and viral meningitis
    Pascal Chavanet
    Service des Maladies Infectieuses, EA 652, University Hospital, Hopital du Bocage, 21000 Dijon, France
    J Infect 54:328-36. 2007
    ..In order to help distinguish these two categories, scoring tools have been proposed that are more or less complex and validated...
  41. ncbi request reprint Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors
    Michel Duong
    Department of Infectious Diseases, Hopital du Bocage, Dijon, France
    Ann Pharmacother 39:603-9. 2005
    ..However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants...
  42. ncbi request reprint Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy
    Michel Duong
    Division of Infectious Diseases, University Hospital, Dijon, France
    HIV Clin Trials 7:41-7. 2006
    ..The aim of the study was to investigate the concentrations of ox-LDL in HIV-infected patients under antiretroviral therapy with (HIV-LD) or without (HIV-nLD) HIV-related lipodystrophy...
  43. doi request reprint [HIV infection in France in 2012: reality, risks and challenges for a chronic multisystem disease]
    M Blot
    Département d infectiologie, CHU de Dijon, 2, Boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    Rev Mal Respir 29:785-92. 2012
    ..Antiretroviral treatment has been a major step forward, subject to accessibility, tolerance and adherence, but it has not solved all the problems associated with this infection, as it becomes a chronic illness...
  44. ncbi request reprint [Pulmonary abscess and Pyoderma gangrenosum]
    A Mirkamali
    Service des Maladies Infectieuses et Tropicales, CHU de Dijon, 10, Boulevard Marechal De Lattre de Tassigny, 21079 Dijon Cedex, France
    Med Mal Infect 37:835-9. 2007
    ..Pyoderma gangrenosum is the ulcerative form of neutrophilic dermatoses. The most frequent extracutaneous localizations are the lungs, joints, and digestive tract...
  45. ncbi request reprint New model of ventilator-associated pneumonia in immunocompetent rabbits
    Pierre Emmanuel Charles
    Service des Maladies Infectieuses, Dijon University Hospital, Faculty of Medicine, France
    Crit Care Med 30:2278-83. 2002
    ..A rabbit model of ventilator-associated pneumonia is described for the first time in this study. DESIGN Prospective, randomized experimental study...
  46. ncbi request reprint In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin
    B Martha
    Division of Infectious Diseases, Hopital du Bocage, University Hospital, 21000 Dijon, France
    Clin Microbiol Infect 12:426-32. 2006
    ..Finally, this model appears to be suitable for the investigation of new anti-pseudomonal therapeutic strategies...
  47. ncbi request reprint Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy
    M Duong
    Service des Maladies Infectieuses, Hopital du Bocage, Dijon 21034, France
    Clin Infect Dis 34:523-8. 2002
    ..Exercise testing might be recommended for patients with HIV who have central fat accumulation and hypercholesterolemia...
  48. ncbi request reprint The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae
    Pierre Emmanuel Charles
    Laboratoire des Maladies Infectieuses, Dijon University Hospital, Dijon, France
    Crit Care Med 33:1029-35. 2005
    ..Our objective was to study to what extent MV could influence the efficacy of moxifloxacin in a rabbit model of pneumonia...
  49. doi request reprint In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia
    Delphine Croisier
    Infectious Diseases Department, University Hospital, Dijon, France
    Int J Antimicrob Agents 32:494-8. 2008
    ..These findings suggest that continuous treatment with 4g CAZ could be appropriate in patients with P. aeruginosa infections...
  50. ncbi request reprint The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients
    Lionel Piroth
    Infectious Diseases Department, Service des Maladies Infectieuses et Tropicales, Hôpital d Enfants, 21034 Dijon Cedex, France
    J Hepatol 36:681-6. 2002
    ..The evolution of hepatitis B virus (HBV) serological patterns and the clinical relevance of isolated anti-HBc pattern are not well established in HIV infected patients...
  51. ncbi request reprint Efficacy of humanlike Augmentin SR (2000/125 mg) twice daily treatment on Haemophilus influenzae experimental pneumonia in rabbits
    Delphine Croisier
    Laboratoire de Maladies Infectieuses, Hopital du Bocage, Dijon, France
    Scand J Infect Dis 39:115-21. 2007
    ..These results support current breakpoints for conventional Augmentin against H. influenzae and suggest that Augmentin SR is at least as effective against these isolates...
  52. pmc Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy
    Delphine Croisier
    Service des Maladies Infectieuses, Microbiologie Médicale et Moléculaire, Hopital du Bocage, 21034 Dijon Cedex, France
    Antimicrob Agents Chemother 48:1699-707. 2004
    ..Since the MPC determination cannot be routinely determined, these phenotypes or genotypes should be detected by simple tests to guide the therapeutic options...
  53. ncbi request reprint In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants
    Delphine Croisier
    Service des Maladies Infectieuses, Microbiologie Médicale et Moléculaire, Hopital du Bocage, 21000 Dijon cedex, France
    J Antimicrob Chemother 54:640-7. 2004
    ..The MSW corresponds to the range of concentrations between the minimal inhibitory concentration (MIC) and the mutant prevention concentration (MPC), which is the antibiotic concentration that prevents selection of resistant mutants...
  54. ncbi request reprint Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits
    Manuel Etienne
    Service des Maladies Infectieuses, Hopital du Bocage, Dijon, France
    J Infect Dis 190:1472-5. 2004
    ..We measured the effect of low-level fluoroquinolone resistance in Streptococcus pneumoniae on the development of high-level resistance within the context of the mutant selection window...
  55. ncbi request reprint Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones
    Delphine Croisier
    Service des Maladies Infectieuses, Microbiologie Médicale et Moléculaire EA562, Hopital du Bocage, BP 1542, 21034 Dijon Cedex, France
    J Antimicrob Chemother 50:349-60. 2002
    ..5 mg/L, ineffective on experimental pneumonia due to pneumococci with MIC > or = 2 mg/L, and could be associated with the appearance of mutants when a parC mutation is pre-existing...
  56. ncbi request reprint Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen
    Vincent Le Moing
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    AIDS 16:21-9. 2002
    ..To study the predictors of virological rebound in patients having early virological response to protease inhibitor (PI)-containing regimen...
  57. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
    ..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients...
  58. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  59. ncbi request reprint [Management of HCV-HIV and HBV-HIV coinfected patients]
    Patrice Cacoub
    Universite Pierre et Marie Curie, Paris 6, CNRS, UMR 7087, Paris, France
    Gastroenterol Clin Biol 31:887-94. 2007
  60. ncbi request reprint Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies...
  61. doi request reprint Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients
    Fabrice Carrat
    UPMC Paris6, UMR S707, INSERM, UMR S707, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, France
    AIDS 22:1513-5. 2008
    ..83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response...
  62. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...